Mai Capital Management Atea Pharmaceuticals, Inc. Transaction History
Mai Capital Management
- $13.2 Billion
- Q4 2024
A detailed history of Mai Capital Management transactions in Atea Pharmaceuticals, Inc. stock. As of the latest transaction made, Mai Capital Management holds 95 shares of AVIR stock, worth $293. This represents 0.0% of its overall portfolio holdings.
Number of Shares
95Holding current value
$293% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding AVIR
# of Institutions
112Shares Held
50.9MCall Options Held
7.6KPut Options Held
38.7K-
Black Rock Inc. New York, NY9.12MShares$28.2 Million0.0% of portfolio
-
Bml Capital Management, LLC Zionsville, IN7.61MShares$23.5 Million15.83% of portfolio
-
Tang Capital Management LLC San Diego, CA4.79MShares$14.8 Million1.21% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.67MShares$14.4 Million0.0% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA3.34MShares$10.3 Million0.52% of portfolio
About Atea Pharmaceuticals, Inc.
- Ticker AVIR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 83,258,600
- Market Cap $257M
- Description
- Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The ...